136 related articles for article (PubMed ID: 29246624)
21. A role for LRIG1 in the regulation of malignant glioma aggressiveness.
Mao F; Wang B; Xiao Q; Xi G; Sun W; Zhang H; Ye F; Wan F; Guo D; Lei T; Chen X
Int J Oncol; 2013 Mar; 42(3):1081-7. PubMed ID: 23337938
[TBL] [Abstract][Full Text] [Related]
22. Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age.
Yi W; Haapasalo H; Holmlund C; Järvelä S; Raheem O; Bergenheim AT; Hedman H; Henriksson R
Clin Neuropathol; 2009; 28(1):21-7. PubMed ID: 19216216
[TBL] [Abstract][Full Text] [Related]
23. Redistribution of LRIG proteins in psoriasis.
Karlsson T; Mark EB; Henriksson R; Hedman H
J Invest Dermatol; 2008 May; 128(5):1192-5. PubMed ID: 18037903
[TBL] [Abstract][Full Text] [Related]
24. LRIG1 enhances cisplatin sensitivity of glioma cell lines.
Wang X; Xiao Q; Xing X; Tian C; Zhang H; Ye F; Wan F; Wang B; Guo D; Lei T
Oncol Res; 2012; 20(5-6):205-11. PubMed ID: 23581227
[TBL] [Abstract][Full Text] [Related]
25. Characterization and tissue-specific expression of human LRIG2.
Holmlund C; Nilsson J; Guo D; Starefeldt A; Golovleva I; Henriksson R; Hedman H
Gene; 2004 May; 332():35-43. PubMed ID: 15145052
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
[TBL] [Abstract][Full Text] [Related]
27. LRIG1 is a prognostic biomarker in non-small cell lung cancer.
Kvarnbrink S; Karlsson T; Edlund K; Botling J; Lindquist D; Jirström K; Micke P; Henriksson R; Johansson M; Hedman H
Acta Oncol; 2015; 54(8):1113-9. PubMed ID: 25813475
[TBL] [Abstract][Full Text] [Related]
28. RIGging functional outcomes in glioma cells: new insights into LRIG proteins in malignant gliomas.
Eisenstat DD; Gibson SB
Cancer Biol Ther; 2009 Jun; 8(11):1024-6. PubMed ID: 19430200
[No Abstract] [Full Text] [Related]
29. Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
Wu X; Hedman H; Bergqvist M; Bergström S; Henriksson R; Gullbo J; Lennartsson J; Hesselius P; Ekman S
Acta Oncol; 2012 Jan; 51(1):69-76. PubMed ID: 21417672
[TBL] [Abstract][Full Text] [Related]
30. A protein interaction network centered on leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) regulates growth factor receptors.
Faraz M; Herdenberg C; Holmlund C; Henriksson R; Hedman H
J Biol Chem; 2018 Mar; 293(9):3421-3435. PubMed ID: 29317492
[TBL] [Abstract][Full Text] [Related]
31. LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.
Zhang X; Song Q; Wei C; Qu J
Cell Stress Chaperones; 2015 Jul; 20(4):631-41. PubMed ID: 25860915
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Role of LRIG Proteins in Endometrial Cancer.
Razumova Z; Oda H; Govorov I; Lundin E; Östensson E; Lindquist D; Mints M
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802837
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation, cell cycle, cell apoptosis, adhesion and invasion of glioblastoma cell (GL15).
Cai M; Han L; Chen R; Ye F; Wang B; Han F; Lei T; Guo D
Cancer Lett; 2009 Jun; 278(1):104-12. PubMed ID: 19200647
[TBL] [Abstract][Full Text] [Related]
34. LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in Glioma.
Peng C; Chen H; Li Y; Yang H; Qin P; Ma B; Duan Q; Wang B; Mao F; Guo D
Front Oncol; 2021; 11():621154. PubMed ID: 33718179
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro.
Wang B; Han L; Chen R; Cai M; Han F; Lei T; Guo D
Cancer Biol Ther; 2009 Jun; 8(11):1018-23. PubMed ID: 19421009
[TBL] [Abstract][Full Text] [Related]
36. LRIG3 modulates proliferation, apoptosis and invasion of glioblastoma cells as a potent tumor suppressor.
Guo D; Yang H; Guo Y; Xiao Q; Mao F; Tan Y; Wan X; Wang B; Lei T
J Neurol Sci; 2015 Mar; 350(1-2):61-8. PubMed ID: 25708990
[TBL] [Abstract][Full Text] [Related]
37. LRIG1 enhances chemosensitivity by modulating BCL-2 expression and receptor tyrosine kinase signaling in glioma cells.
Guo Z; Chen Q; Liu B; Tian D; Zhang S; Li M
Yonsei Med J; 2014 Sep; 55(5):1196-205. PubMed ID: 25048475
[TBL] [Abstract][Full Text] [Related]
38. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
[TBL] [Abstract][Full Text] [Related]
39. Low-grade glioma risk SNP rs11706832 is associated with type I interferon response pathway genes in cell lines.
Rosenbaum A; Dahlin AM; Andersson U; Björkblom B; Wu WY; Hedman H; Wibom C; Melin B
Sci Rep; 2023 Apr; 13(1):6777. PubMed ID: 37185361
[TBL] [Abstract][Full Text] [Related]
40. Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy.
Neirinckx V; Hedman H; Niclou SP
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):109-116. PubMed ID: 28259645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
